Agnes Schonbrunn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Agnes Schonbrunn has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Madhumita Ghosh
Department of Integrative Biology and Pharmacology, University of Texas, Health Science Center-Houston, Houston, Texas 77030
3 shared publicationsQisheng Liu
Department of Integrative Biology and Pharmacology, University of Texas-Houston, School of Medicine, Houston, TX 77225, USA
3 shared publications- Jean Claude Reubi
Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Berne, Switzerland
2 shared publications Renzo Cescato
Division of Cell Biology, Institute of Pathology, University of Berne, Berne, Switzerland
2 shared publicationsBeatrice Waser
Division of Cell Biology and Experimental Cancer Research (R.C., B.W., J.C.R.), Institute of Pathology, University of Berne, CH-3010 Berne, Switzerland
1 shared publication- Beatrice Waser
Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, PO Box 62, Murtenstrasse 31, CH-3010, Berne, Switzerland
1 shared publication
Latest Publications
- Open Access
- 1 September 2015
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 29 (9) , 1219-1221
Editorial: Reproducibility in Research: A Cautionary Tale and Lessons Not Learned
The 1970s and 1980s were a transformative period for neuroendocrine research. During these 2 decades, many of the hypothalamic peptides regulating pituitary hormone secretion were identified and the field exploded with studies characterizing the spectrum of their biological activities. In the race to these exciting discoveries, discordant results were published regarding the central actions of the newly discovered GH-releasing factor (GRF). Two groups reported a biphasic effect of central administration of human GRF with low doses suppressing and high doses stimulating GH release in rats (1, 2). In contrast, a third group reported that administration of both low and high doses of human GRF inhibited GH secretion (3). Through meticulous scientific detective work, the source of the discrepancy was uncovered and, in the best scientific tradition, promptly published (4). Chemical characterization of the peptide that produced GH inhibition at all doses demonstrated that the putative GRF peptide consisted predominantly of corticotropin-releasing factor. Furthermore, use of new GRF samples reproduced the previously reported stimulatory effect on GH. Although how the original sample became contaminated is not known (4, 5), the source of this error is irrelevant for the purpose of scientific progress: the truth was discovered and revealed.
- 1 September 2015
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 29 (9) , 1219-1221
Open AccessEditorial: Reproducibility in Research: A Cautionary Tale and Lessons Not Learned
The 1970s and 1980s were a transformative period for neuroendocrine research. During these 2 decades, many of the hypothalamic peptides regulating pituitary hormone secretion were identified and the field exploded with studies characterizing the spectrum of their biological activities. In the race to these exciting discoveries, discordant results were published regarding the central actions of the newly discovered GH-releasing factor (GRF). Two groups reported a biphasic effect of central administration of human GRF with low doses suppressing and high doses stimulating GH release in rats (1, 2). In contrast, a third group reported that administration of both low and high doses of human GRF inhibited GH secretion (3). Through meticulous scientific detective work, the source of the discrepancy was uncovered and, in the best scientific tradition, promptly published (4). Chemical characterization of the peptide that produced GH inhibition at all doses demonstrated that the putative GRF peptide consisted predominantly of corticotropin-releasing factor. Furthermore, use of new GRF samples reproduced the previously reported stimulatory effect on GH. Although how the original sample became contaminated is not known (4, 5), the source of this error is irrelevant for the purpose of scientific progress: the truth was discovered and revealed.
- Open Access
- 1 September 2014
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 28 (9) , 1403-1407
Editorial: Antibody Can Get It Right: Confronting Problems of Antibody Specificity and Irreproducibility
Antibodies are extremely powerful and sensitive reagents that provide the foundation on which many different molecular studies are built. However, they are capa
- 1 September 2014
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 28 (9) , 1403-1407
Open AccessEditorial: Antibody Can Get It Right: Confronting Problems of Antibody Specificity and Irreproducibility
Antibodies are extremely powerful and sensitive reagents that provide the foundation on which many different molecular studies are built. However, they are capa
- 1 December 2013
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 34 (12) , 676-688
Illuminating somatostatin analog action at neuroendocrine tumor receptors
- 1 December 2013
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 34 (12) , 676-688
Illuminating somatostatin analog action at neuroendocrine tumor receptors
- Open Access
- 1 June 2011
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 25 (6) , 1040-1054
Ligand-Dependent Mechanisms of sst2A Receptor Trafficking: Role of Site-Specific Phosphorylation and Receptor Activation in the Actions of Biased Somatostatin Agonists
The somatostatin receptor subtype 2A (sst2A) mediates many of somatostatin's neuroendocrine actions and is the primary therapeutic target for the stable somatostatin analogs used to inhibit hormone secretion by pituitary and gastroenteropancreatic tumors. Two new multireceptor targeting somatostatin analogs currently under clinical investigation, the multisomatostatin receptor agonist cyclo-[diaminoethylcarbamoyl-HydroxyPro-Phenylglycine-D-Trp-Lys-(4-O-benzyl)Tyr-Phe] (SOM230) (Pasireotide) and pan-somatostatin receptor agonist Tyr-cyclo-[D-diaminobutyric acid-Arg-Phe-Phe-D-Trp-Lys-Thr-Phe] (KE108), behave as functionally selective ligands at the sst2A receptor, mimicking some of somatostatin's actions but antagonizing others. Further, SOM230 and KE108 are less able to induce receptor internalization than somatostatin, indicating that they exhibit functional selectivity for receptor regulation as well as signaling. Here, we identify agonist-specific differences in the molecular events regulating sst2A receptor endocytosis. SOM230 and KE108 were less potent and less effective than somatostatin at stimulating sst2A receptor phosphorylation at two pairs of residues, Ser341/343 and Thr353/354. Only the pattern of Thr353/354 phosphorylation correlated with receptor internalization, consistent with the known importance of Thr phosphorylation for sst2A receptor endocytosis. As expected, arrestin recruitment to membrane receptors was reduced with SOM230 and KE108. In addition, both receptor dephosphorylation and receptor recycling occurred more rapidly with SOM230 and KE108 than with somatostatin. Surprisingly, however, SOM230 and KE108 also altered sst2A internalization in a phosphorylation-independent manner, because these analogs were less effective than somatostatin at stimulating the endocytosis of a phosphorylation-negative receptor mutant. These results show that the decreased receptor internalization produced by SOM230 and KE108 compared with somatostatin result from phosphorylation-independent effects as well as reduced site-specific receptor phosphorylation and receptor-arrestin association.
- 1 June 2011
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 25 (6) , 1040-1054
Open AccessLigand-Dependent Mechanisms of sst2A Receptor Trafficking: Role of Site-Specific Phosphorylation and Receptor Activation in the Actions of Biased Somatostatin Agonists
The somatostatin receptor subtype 2A (sst2A) mediates many of somatostatin's neuroendocrine actions and is the primary therapeutic target for the stable somatostatin analogs used to inhibit hormone secretion by pituitary and gastroenteropancreatic tumors. Two new multireceptor targeting somatostatin analogs currently under clinical investigation, the multisomatostatin receptor agonist cyclo-[diaminoethylcarbamoyl-HydroxyPro-Phenylglycine-D-Trp-Lys-(4-O-benzyl)Tyr-Phe] (SOM230) (Pasireotide) and pan-somatostatin receptor agonist Tyr-cyclo-[D-diaminobutyric acid-Arg-Phe-Phe-D-Trp-Lys-Thr-Phe] (KE108), behave as functionally selective ligands at the sst2A receptor, mimicking some of somatostatin's actions but antagonizing others. Further, SOM230 and KE108 are less able to induce receptor internalization than somatostatin, indicating that they exhibit functional selectivity for receptor regulation as well as signaling. Here, we identify agonist-specific differences in the molecular events regulating sst2A receptor endocytosis. SOM230 and KE108 were less potent and less effective than somatostatin at stimulating sst2A receptor phosphorylation at two pairs of residues, Ser341/343 and Thr353/354. Only the pattern of Thr353/354 phosphorylation correlated with receptor internalization, consistent with the known importance of Thr phosphorylation for sst2A receptor endocytosis. As expected, arrestin recruitment to membrane receptors was reduced with SOM230 and KE108. In addition, both receptor dephosphorylation and receptor recycling occurred more rapidly with SOM230 and KE108 than with somatostatin. Surprisingly, however, SOM230 and KE108 also altered sst2A internalization in a phosphorylation-independent manner, because these analogs were less effective than somatostatin at stimulating the endocytosis of a phosphorylation-negative receptor mutant. These results show that the decreased receptor internalization produced by SOM230 and KE108 compared with somatostatin result from phosphorylation-independent effects as well as reduced site-specific receptor phosphorylation and receptor-arrestin association.
- 1 June 2011
- Published by The Endocrine Society
- p. OR41-1
Temporal and Spatial Regulation of Site-Specific Somatostatin Receptor Phosphorylation
G protein coupled receptors (GPCRs) are stringently regulated by phosphorylation of multiple Ser and Thr residues within their intracellular domains. Previous studies have shown that phosphorylation at different sites has distinct consequences for receptor activity, such that the functional state of a receptor is determined by the particular phosphorylated species that exist: a so-called phosphorylation bar code. The somatostatin 2A receptor (sst2A) mediates many of the neuromodulatory and neuroendocrine actions of somatostatin (SS) and is the target for the SS analogs used to treat neuroendocrine tumors. Not only does phosphorylation of different sites produce distinct effects on sst2A receptor internalization and uncoupling but different agonists produce specific patterns of sst2A receptor phosphorylation. To elucidate the spatial and temporal regulation of sst2A phosphorylation, we examined agonist-stimulated phosphorylation of multiple sites using phospho-site specific antibodies. SS increased sst2A receptor phosphorylation sequentially, first on S341/343 and then on T353/354. Phosphorylation of all residues preceded receptor internalization. Unexpectedly, reversal of receptor phosphorylation was determined by the duration of prior agonist exposure. In acutely stimulated cells, when most receptors remained on the cell surface, dephosphorylation occurred only on T353/354. In contrast, both S341/343 and T353/354 were rapidly dephosphorylated when cells were stimulated long enough to allow receptor internalization before agonist removal. Consistent with these results, dephosphorylation of T353/354 was not affected by agents that block receptor internalization whereas dephosphorylation of S341/343 was completely inhibited. Thus, receptor endocytosis is essential for full reactivation of sst2A receptors after agonist-induced phosphorylation. An okadaic acid sensitive phosphatase catalyzed dephosphorylation of T353/354 both intracellularly and at the cell surface. In contrast, dephosphorylation of S341/343 was insensitive to this inhibitor, showing that a different phosphatase was involved. Together, our results demonstrate that the phosphorylation and dephosphorylation of neighboring GRK sites in the sst2A receptor are subject to specific spatial, temporal, and enzymatic regulation. As a result, the pattern of sst2A receptor phosphorylation is determined by the duration of agonist stimulation and the subcellular localization of the receptor. Sources of Research Support: NIH grant DK032234. Nothing to Disclose: MG, AS
- 1 June 2011
- Published by The Endocrine Society
- p. OR41-1
Temporal and Spatial Regulation of Site-Specific Somatostatin Receptor Phosphorylation
G protein coupled receptors (GPCRs) are stringently regulated by phosphorylation of multiple Ser and Thr residues within their intracellular domains. Previous studies have shown that phosphorylation at different sites has distinct consequences for receptor activity, such that the functional state of a receptor is determined by the particular phosphorylated species that exist: a so-called phosphorylation bar code. The somatostatin 2A receptor (sst2A) mediates many of the neuromodulatory and neuroendocrine actions of somatostatin (SS) and is the target for the SS analogs used to treat neuroendocrine tumors. Not only does phosphorylation of different sites produce distinct effects on sst2A receptor internalization and uncoupling but different agonists produce specific patterns of sst2A receptor phosphorylation. To elucidate the spatial and temporal regulation of sst2A phosphorylation, we examined agonist-stimulated phosphorylation of multiple sites using phospho-site specific antibodies. SS increased sst2A receptor phosphorylation sequentially, first on S341/343 and then on T353/354. Phosphorylation of all residues preceded receptor internalization. Unexpectedly, reversal of receptor phosphorylation was determined by the duration of prior agonist exposure. In acutely stimulated cells, when most receptors remained on the cell surface, dephosphorylation occurred only on T353/354. In contrast, both S341/343 and T353/354 were rapidly dephosphorylated when cells were stimulated long enough to allow receptor internalization before agonist removal. Consistent with these results, dephosphorylation of T353/354 was not affected by agents that block receptor internalization whereas dephosphorylation of S341/343 was completely inhibited. Thus, receptor endocytosis is essential for full reactivation of sst2A receptors after agonist-induced phosphorylation. An okadaic acid sensitive phosphatase catalyzed dephosphorylation of T353/354 both intracellularly and at the cell surface. In contrast, dephosphorylation of S341/343 was insensitive to this inhibitor, showing that a different phosphatase was involved. Together, our results demonstrate that the phosphorylation and dephosphorylation of neighboring GRK sites in the sst2A receptor are subject to specific spatial, temporal, and enzymatic regulation. As a result, the pattern of sst2A receptor phosphorylation is determined by the duration of agonist stimulation and the subcellular localization of the receptor. Sources of Research Support: NIH grant DK032234. Nothing to Disclose: MG, AS
- Open Access
- 1 April 2011
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 286 (15) , 13561-13573
Differential Temporal and Spatial Regulation of Somatostatin Receptor Phosphorylation and Dephosphorylation
- 1 April 2011
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 286 (15) , 13561-13573
Open AccessDifferential Temporal and Spatial Regulation of Somatostatin Receptor Phosphorylation and Dephosphorylation
- Open Access
- 1 January 2010
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 24 (1) , 240-249
Agonist-Biased Signaling at the sst2A Receptor: The Multi-Somatostatin Analogs KE108 and SOM230 Activate and Antagonize Distinct Signaling Pathways
Somatostatin analogs that activate the somatostatin subtype 2A (sst2A) receptor are used to treat neuroendocrine cancers because they inhibit tumor secretion and growth. Recently, new analogs capable of activating multiple somatostatin receptor subtypes have been developed to increase tumor responsiveness. We tested two such multi-somatostatin analogs for functional selectivity at the sst2A receptor: SOM230, which activates sst1, sst2, sst3, and sst5 receptors, and KE108, which activates all sst receptor subtypes. Both compounds are reported to act as full agonists at their target sst receptors. In sst2A-expressing HEK293 cells, somatostatin inhibited cAMP production, stimulated intracellular calcium accumulation, and increased ERK phosphorylation. SOM230 and KE108 were also potent inhibitors of cAMP accumulation, as expected. However, they antagonized somatostatin stimulation of intracellular calcium and behaved as partial agonists/antagonists for ERK phosphorylation. In pancreatic AR42J cells, which express sst2A receptors endogenously, SOM230 and KE108 were both full agonists for cAMP inhibition. However, although somatostatin increased intracellular calcium and ERK phosphorylation, SOM230 and KE108 again antagonized these effects. Distinct mechanisms were involved in sst2A receptor signaling in AR42J cells; pertussis toxin pretreatment blocked somatostatin inhibition of cAMP accumulation but not the stimulation of intracellular calcium and ERK phosphorylation. Our results demonstrate that SOM230 and KE108 behave as agonists for inhibition of adenylyl cyclase but antagonize somatostatin’s actions on intracellular calcium and ERK phosphorylation. Thus, SOM230 and KE108 are not somatostatin mimics, and their functional selectivity at sst2A receptors must be considered in clinical applications where it may have important consequences for therapy.
- 1 January 2010
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 24 (1) , 240-249
Open AccessAgonist-Biased Signaling at the sst2A Receptor: The Multi-Somatostatin Analogs KE108 and SOM230 Activate and Antagonize Distinct Signaling Pathways
Somatostatin analogs that activate the somatostatin subtype 2A (sst2A) receptor are used to treat neuroendocrine cancers because they inhibit tumor secretion and growth. Recently, new analogs capable of activating multiple somatostatin receptor subtypes have been developed to increase tumor responsiveness. We tested two such multi-somatostatin analogs for functional selectivity at the sst2A receptor: SOM230, which activates sst1, sst2, sst3, and sst5 receptors, and KE108, which activates all sst receptor subtypes. Both compounds are reported to act as full agonists at their target sst receptors. In sst2A-expressing HEK293 cells, somatostatin inhibited cAMP production, stimulated intracellular calcium accumulation, and increased ERK phosphorylation. SOM230 and KE108 were also potent inhibitors of cAMP accumulation, as expected. However, they antagonized somatostatin stimulation of intracellular calcium and behaved as partial agonists/antagonists for ERK phosphorylation. In pancreatic AR42J cells, which express sst2A receptors endogenously, SOM230 and KE108 were both full agonists for cAMP inhibition. However, although somatostatin increased intracellular calcium and ERK phosphorylation, SOM230 and KE108 again antagonized these effects. Distinct mechanisms were involved in sst2A receptor signaling in AR42J cells; pertussis toxin pretreatment blocked somatostatin inhibition of cAMP accumulation but not the stimulation of intracellular calcium and ERK phosphorylation. Our results demonstrate that SOM230 and KE108 behave as agonists for inhibition of adenylyl cyclase but antagonize somatostatin’s actions on intracellular calcium and ERK phosphorylation. Thus, SOM230 and KE108 are not somatostatin mimics, and their functional selectivity at sst2A receptors must be considered in clinical applications where it may have important consequences for therapy.
- 1 July 2009
- Published by Elsevier in Molecular Pharmacology
- Vol. 76 (1) , 68-80
Site Specificity of Agonist and Second Messenger-Activated Kinases for Somatostatin Receptor Subtype 2A (Sst2A) Phosphorylation
Somatostatin receptor subtype 2A (sst2A) mediates many of the endocrine and neuronal actions of somatostatin and is the target of somatostatin analogs in cancer therapy. As with many G-protein-coupled receptors, agonist stimulation causes sst2A receptor desensitization and internalization, events that require receptor phosphorylation. Furthermore, heterologous receptor activation of protein kinase C (PKC) also increases sst2A receptor phosphorylation and internalization. Here we analyzed a series of sst2A receptor mutants biochemically to identify residues in the receptor carboxyl terminus that were phosphorylated upon agonist stimulation, and we then generated four phosphorylation-sensitive antibodies to those residues. Once the selectivity of each antibody for its phosphorylated and nonphosphorylated target sequence was determined, the phospho-site-specific antibodies were used to demonstrate that somatostatin treatment of Chinese hamster ovary (CHO) cells expressing the wild type sst2A receptor increased phosphorylation on five residues in the receptor C terminus: Ser341, Ser343, Ser348, Thr353, and Thr354. Phorbol 12-myristate 13-acetate (PMA) increased receptor phosphorylation only on Ser343. Inhibition of PKC blocked PMA but not somatostatin stimulation, showing that different kinases catalyzed Ser343 phosphorylation. In contrast, somatostatin-stimulated sst2A receptor phosphorylation was inhibited by knockdown of G-protein coupled receptor kinase-2 with siRNA. Somatostatin increased sst2A receptor phosphorylation on the same five residues in GH4C1 pituitary cells as in CHO cells. However, PMA stimulated sst2A receptor phosphorylation on both Ser343 and Ser348 in GH4C1 cells. These results characterize the complex pattern of sst2A receptor phosphorylation by agonist and second messenger-activated kinases for the first time and indicate that cell type-specific regulation of sst2A receptor phosphorylation occurs.
- 1 July 2009
- Published by Elsevier in Molecular Pharmacology
- Vol. 76 (1) , 68-80
Site Specificity of Agonist and Second Messenger-Activated Kinases for Somatostatin Receptor Subtype 2A (Sst2A) Phosphorylation
Somatostatin receptor subtype 2A (sst2A) mediates many of the endocrine and neuronal actions of somatostatin and is the target of somatostatin analogs in cancer therapy. As with many G-protein-coupled receptors, agonist stimulation causes sst2A receptor desensitization and internalization, events that require receptor phosphorylation. Furthermore, heterologous receptor activation of protein kinase C (PKC) also increases sst2A receptor phosphorylation and internalization. Here we analyzed a series of sst2A receptor mutants biochemically to identify residues in the receptor carboxyl terminus that were phosphorylated upon agonist stimulation, and we then generated four phosphorylation-sensitive antibodies to those residues. Once the selectivity of each antibody for its phosphorylated and nonphosphorylated target sequence was determined, the phospho-site-specific antibodies were used to demonstrate that somatostatin treatment of Chinese hamster ovary (CHO) cells expressing the wild type sst2A receptor increased phosphorylation on five residues in the receptor C terminus: Ser341, Ser343, Ser348, Thr353, and Thr354. Phorbol 12-myristate 13-acetate (PMA) increased receptor phosphorylation only on Ser343. Inhibition of PKC blocked PMA but not somatostatin stimulation, showing that different kinases catalyzed Ser343 phosphorylation. In contrast, somatostatin-stimulated sst2A receptor phosphorylation was inhibited by knockdown of G-protein coupled receptor kinase-2 with siRNA. Somatostatin increased sst2A receptor phosphorylation on the same five residues in GH4C1 pituitary cells as in CHO cells. However, PMA stimulated sst2A receptor phosphorylation on both Ser343 and Ser348 in GH4C1 cells. These results characterize the complex pattern of sst2A receptor phosphorylation by agonist and second messenger-activated kinases for the first time and indicate that cell type-specific regulation of sst2A receptor phosphorylation occurs.
- 1 May 2008
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 286 (1-2) , 35-39
Selective agonism in somatostatin receptor signaling and regulation
- 1 May 2008
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 286 (1-2) , 35-39
Selective agonism in somatostatin receptor signaling and regulation
- Open Access
- 1 July 2005
- Published by Elsevier in Molecular Pharmacology
- Vol. 68 (1) , 90-101
Receptor Signaling and Endocytosis Are Differentially Regulated by Somatostatin Analogs
Upon hormone stimulation, the sst2 somatostatin receptor couples to adenylyl cyclase through Gi/o proteins and undergoes rapid endocytosis via clathrin-coated pits. In this study, we determined the relationship between the ability of ligands to induce sst2 receptor internalization and inhibit adenylyl cyclase. Immunocytochemical studies demonstrated that peptide agonists [such as somatostatin-14, cortistatin-17, octreotide, vapreotide, KE108 (Tyr0-cyclo[d-diaminobutyric acid-Arg-Phe-Phe-d-Trp-Lys-Thr-Phe]), and SOM230 (cyclo[diaminoethylcarbamoyl-hydroxyproline-phenylglycine-d-Trp-Lys-(4-O-benzyl)-l-Tyr-Phe])] and nonpeptide agonists (such as L-779,976), stimulated the rapid endocytosis of sst2 receptors in human embryonic kidney 293 and CHO-K1 cells. In contrast, two antagonists did not induce receptor endocytosis by themselves and completely blocked agonist stimulation. Using a quantitative enzyme-linked immunosorbent assay to measure sst2 receptor sequestration, we found that peptide agonists varied by more than 100-fold in their potencies but exhibited the same efficacy as somatostatin14. In contrast, L-779,976 did not induce maximal receptor internalization. It is interesting that although βarrestin-2 was recruited to cell surface sst2 receptors after stimulation with either somatostatin14 or L-779,976, the βarrestin-receptor complex dissociated earlier in the endocytic pathway with the nonpeptide ligand. Although all agonists, including L-779,976, produced the same maximal inhibition of cyclic AMP, the potency ratio for inhibition of cyclic AMP and stimulation of receptor endocytosis varied by 15-fold. In general, native peptides showed similar potencies for cyclic AMP inhibition and receptor endocytosis, whereas short therapeutic analogs were substantially more potent at inhibiting cyclic AMP synthesis. These results demonstrate that the activity of somatostatin analogs to regulate receptor endocytosis and signaling are not tightly linked and provide compelling evidence for the induction of agonist specific states of the sst2 receptor.
- 1 July 2005
- Published by Elsevier in Molecular Pharmacology
- Vol. 68 (1) , 90-101
Open AccessReceptor Signaling and Endocytosis Are Differentially Regulated by Somatostatin Analogs
Upon hormone stimulation, the sst2 somatostatin receptor couples to adenylyl cyclase through Gi/o proteins and undergoes rapid endocytosis via clathrin-coated pits. In this study, we determined the relationship between the ability of ligands to induce sst2 receptor internalization and inhibit adenylyl cyclase. Immunocytochemical studies demonstrated that peptide agonists [such as somatostatin-14, cortistatin-17, octreotide, vapreotide, KE108 (Tyr0-cyclo[d-diaminobutyric acid-Arg-Phe-Phe-d-Trp-Lys-Thr-Phe]), and SOM230 (cyclo[diaminoethylcarbamoyl-hydroxyproline-phenylglycine-d-Trp-Lys-(4-O-benzyl)-l-Tyr-Phe])] and nonpeptide agonists (such as L-779,976), stimulated the rapid endocytosis of sst2 receptors in human embryonic kidney 293 and CHO-K1 cells. In contrast, two antagonists did not induce receptor endocytosis by themselves and completely blocked agonist stimulation. Using a quantitative enzyme-linked immunosorbent assay to measure sst2 receptor sequestration, we found that peptide agonists varied by more than 100-fold in their potencies but exhibited the same efficacy as somatostatin14. In contrast, L-779,976 did not induce maximal receptor internalization. It is interesting that although βarrestin-2 was recruited to cell surface sst2 receptors after stimulation with either somatostatin14 or L-779,976, the βarrestin-receptor complex dissociated earlier in the endocytic pathway with the nonpeptide ligand. Although all agonists, including L-779,976, produced the same maximal inhibition of cyclic AMP, the potency ratio for inhibition of cyclic AMP and stimulation of receptor endocytosis varied by 15-fold. In general, native peptides showed similar potencies for cyclic AMP inhibition and receptor endocytosis, whereas short therapeutic analogs were substantially more potent at inhibiting cyclic AMP synthesis. These results demonstrate that the activity of somatostatin analogs to regulate receptor endocytosis and signaling are not tightly linked and provide compelling evidence for the induction of agonist specific states of the sst2 receptor.